(Q38592137)

4 September 2017

0 references

Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis (English)

1 reference

4 September 2017

0 references

1 reference

1 reference

5

Harald Hampel

1 reference

4 September 2017

6

Nakao Iwata

1 reference

4 September 2017

Shinji Matsunaga

1

1 reference

4 September 2017

Taro Kishi

series ordinal

2

1 reference

4 September 2017

Peter Annas

series ordinal

3

1 reference

4 September 2017

Hans Basun

series ordinal

4

1 reference

4 September 2017

publication date

1 September 2015

1 reference

Journal of Alzheimer's Disease

4 September 2017

published in

1 reference

4 September 2017

volume

48

1 reference

4 September 2017

issue

2

1 reference

4 September 2017

page(s)

403-410

1 reference

A molecular mechanism for the effect of lithium on development

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150437

Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150437

Molecular targets of lithium action

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150437

Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150437

Lithium reduces tau phosphorylation: effects in living cells and in neurons at therapeutic concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150437

Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150437

Does lithium protect against dementia?

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150437

Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150437

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150437

Meta-analysis in clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150437

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150437

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150437

Long-term, low-dose lithium treatment does not impair renal function in the elderly: a 2-year randomized, placebo-controlled trial followed by single-blind extension.

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150437

Transdermal is better than oral: observational research of the satisfaction of caregivers of patients with Alzheimer's disease treated with rivastigmine

21 January 2018

1 reference

https://api.crossref.org/works/10.3233%2FJAD-150437

21 January 2018

Identifiers

DOI

10.3233/JAD-150437

1 reference

release_ojtsa6yiq5ande7cgzeravi4km

4 September 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ojtsa6yiq5ande7cgzeravi4km

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference